Effect of Nocturnal Parenteral Nutrition on Bone Turnover and Energy Metabolism (NutriSync)
The Effect of Parenteral Nutrition During Nighttime Versus Daytime on Bone Turnover and Energy Metabolism in Intestinal Failure Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Objective: This randomized crossover pilot study aims to determine the effect of nocturnal versus daytime cyclic infusion of parenteral nutrition in adult patients with chronic intestinal failure on bone turnover, glucose metabolism, nitrogen balance, sleep and wake rhythm and clock genes expression.
This study will include 20 adult patients with chronic intestinal failure. Patients will receive nocturnal parenteral nutrition for 2 weeks (period A) and will switch to daytime parenteral nutrition (period B) for 2 weeks (random assignment). During both study periods glucose variability and sleep / wake rhythm will be measured. After both study periods, patients will be admitted to the metabolic unit for 24 hours to measure bone turnover markers, nitrogen balance, glucoregulatory hormones, energy expenditure and substrate oxidation rates and clock gene expression in leukocytes.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: M.J.M. Serlie, professor
- Phone Number: +31205669111
- Email: m.j.m.serlie@amsterdamumc.nl
Study Contact Backup
- Name: P.H.L.T. Bisschop, professor
- Phone Number: +31205669111
- Email: p.h.bissschop@amsterdamumc.nl
Study Locations
-
-
North Holland
-
Amsterdam, North Holland, Netherlands, 1105AZ
- Recruiting
- Amsterdam University Medical Center
-
Contact:
- GM van der Werf, MSc
- Phone Number: +31205665120
- Email: g.m.vanderwerf@amsterdamumc.nl
-
Contact:
- M.J. Serlie, prof
- Phone Number: +31205666071
- Email: m.j.serlie@amsterdamumc.nl
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Home parenteral nutrition for at least 5 nights a week
- On home parenteral nutrition for more than 1 year
- No major changes in parenteral nutrition for 3 months prior to inclusion
Exclusion Criteria:
- Parenteral infusion for more than 16 h a day
- Use of bone modifying drugs in the last 2 years
- Bone fractures in the past year
- Renal insufficiency (eGFR < 60 ml/min)
- HbA1c ≥48 mmol/ml
- Use of corticosteroids
- Shift work
- Performing intensive exercise (> 2 hours a day and > 3 times a week)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Nocturnal parenteral nutrition
Patients will receive nocturnal parenteral nutrition, starting at 8pm
|
Parenteral nutrition will be administered starting at 8 pm
Other Names:
Parenteral nutrition will be administered starting at 8 am
Other Names:
|
|
Experimental: Diurnal parenteral nutrition
Patients will receive diurnal parenteral nutrition, starting at 8am
|
Parenteral nutrition will be administered starting at 8 pm
Other Names:
Parenteral nutrition will be administered starting at 8 am
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in bone turnover marker Procollagen 1 Intact N-Terminal Propeptide
Time Frame: Study day 1 versus study day 2
|
Differences in the bone turnover marker Procollagen 1 Intact N-Terminal Propeptide (ug/L)
|
Study day 1 versus study day 2
|
|
Differences in bone turnover marker carboxy-terminal collagen crosslinks
Time Frame: Study day 1 versus study day 2
|
Differences in bone turnover marker carboxy-terminal collagen crosslinks (ng/L)
|
Study day 1 versus study day 2
|
|
Changes in glucose variability
Time Frame: 2 weeks versus 2 weeks
|
Changes in glucose variability measured by a continuous glucose monitor
|
2 weeks versus 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in plasma insulin
Time Frame: Study day 1 versus study day 2
|
insulin (pmol/L)
|
Study day 1 versus study day 2
|
|
Changes in plasma glucagon
Time Frame: Study day 1 versus study day 2
|
glucagon (ng/L)
|
Study day 1 versus study day 2
|
|
Changes in nitrogen balance
Time Frame: Study day 1 versus study day 2
|
Changes in nitrogen balance by comparing output (feces/urine) versus intake (oral/enteral/parenteral)
|
Study day 1 versus study day 2
|
|
Changes in sleep/wake rhythm
Time Frame: 2 weeks versus 2 weeks
|
Changes in sleep/wake rhythm measured by an actigraph
|
2 weeks versus 2 weeks
|
|
Changes in clock gene expression
Time Frame: Study day 1 versus study day 2
|
Changes in clock gene expression in leukocytes (if feasible; pilot)
|
Study day 1 versus study day 2
|
|
Changes in energy expenditure
Time Frame: Study day 1 versus study day 2
|
Changes in energy expenditure assessed by indirect calorimetry (kcal/24h)
|
Study day 1 versus study day 2
|
|
Changes in sleep quality
Time Frame: 2 weeks versus 2 weeks
|
Changes in sleep quality, measured by Visual Analogue Scale (VAS) score (scale 1-10, higher scores mean better outcome)
|
2 weeks versus 2 weeks
|
|
Changes in substrate oxidation rates
Time Frame: Study day 1 versus study day 2
|
Changes in substrate oxidation rates assessed by indirect calorimetry (percent)
|
Study day 1 versus study day 2
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in body temperature
Time Frame: Study day 1 versus study day 2
|
Changes in body temperature measured by i-buttons (Celsius)
|
Study day 1 versus study day 2
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: G.M. vd Werf, MSc, RD, Amsterdam UMC, location AMC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 82280.018.22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.